Analyst Price Targets — AVBP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 10, 2025 11:42 am | — | BTIG | $45.00 | $24.91 | TheFly | ArriVent Biopharma initiated with a Buy at BTIG on firmonertinib potential |
| November 25, 2025 11:23 am | — | Truist Financial | $43.00 | $21.51 | TheFly | ArriVent Biopharma initiated with a Buy at Truist |
| July 10, 2025 9:03 am | Corinne Johnson | Goldman Sachs | $33.00 | $22.03 | TheFly | ArriVent Biopharma resumed with a Buy at Goldman Sachs |
| September 10, 2024 11:49 am | Yigal Nochomovitz | Citigroup | $36.00 | $27.93 | StreetInsider | ArriVent BioPharma (AVBP) PT Raised to $36 at Citi |
| September 10, 2024 6:38 am | Robert Burns | H.C. Wainwright | $36.00 | $28.04 | StreetInsider | ArriVent BioPharma (AVBP) PT Raised to $36 at H.C. Wainwright |
| August 16, 2024 6:39 am | Robert Burns | H.C. Wainwright | $30.00 | $23.62 | StreetInsider | ArriVent BioPharma (AVBP) PT Raised to $30 at H.C. Wainwright |
| July 22, 2024 7:05 am | Jeff Jones | Oppenheimer | $35.00 | $18.77 | StreetInsider | Oppenheimer Starts ArriVent BioPharma (AVBP) at Outperform |
Latest News for AVBP
Does ArriVent BioPharma, Inc. (AVBP) have what it takes to be a top stock pick for momentum investors? Let's find out.
The mean of analysts' price targets for ArriVent BioPharma, Inc. (AVBP) points to a 72.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here is how ArriVent BioPharma, Inc. (AVBP) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
The readout for Firmonertinib has moved to mid-2026, which may reflect slower event accumulation and potentially longer progression-free survival compared with the current standard of care. If the drug delivers PFS above ~10 months with statistical significance, Firmonertinib could capture meaningful market share thanks to its oral monotherapy profile and potentially better safety relative to Rybrevant. With $312…
NEWTOWN SQUARE, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced two poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California April 17-22.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AVBP.
U.S. House Trading
No House trades found for AVBP.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.